Modified FGF-21 polypeptides with non-naturally encoded amino acids

Inventors

Cujec, Thomas P. • Mariani, Roberto • HAYS PUTNAM, Anna-Maria A. • KEEFE, William M. • Knudsen, Nick • Skidmore, Lillian • PINKSTAFF, Jason • Kraynov, Vadim

Assignees

Ambrx Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11993637-B2

Patent

Publication Date

2024-05-28

Expiration Date


Abstract

Modified FGF-21 polypeptides and uses thereof are provided.

Core Innovation

The invention relates to modified FGF-21 polypeptides that maintain the biological activity of human FGF-21 while incorporating a non-naturally encoded amino acid. The modified FGF-21 polypeptides comprise a sequence at least 95% identical to SEQ ID NO: 1 through SEQ ID NO: 7, and the non-naturally encoded amino acid is substituted at a position corresponding to residue 72, 77, 86, 108, 110, 131, or 146 of SEQ ID NO: 1.

The non-naturally encoded amino acid is linked to a linker or a polymer, including poly(ethylene glycol), and the patent text describes polymer-linked and polymer-conjugated forms. The disclosure defines the non-naturally encoded amino acid by structural formulas and R-group restrictions, and also references linker or connector groups such as alkylene or N-substituted alkylene.

A key aspect of the invention is that the modified FGF-21 polypeptide has an in vivo half-life at least two-fold greater than the human FGF-21 polypeptide in SEQ ID NO: 1. The patent text also references receptor affinity, glucose uptake in adipocyte contexts, in vivo half-life and pharmacokinetic evaluation, therapeutic use, and formulation concepts.

Claims Coverage

The independent claim coverage centers on modified FGF-21 polypeptides with six inventive features: maintained biological activity, a sequence at least 95% identical to specified SEQ ID NO entries, a non-naturally encoded amino acid with restricted structure, substitution at specified residue positions, linkage to a linker or polymer, and an in vivo half-life at least two-fold greater than human FGF-21. Dependent claims refine the polymer embodiment, including PEG and PEG molecular-weight range, and add a pharmaceutical composition aspect.

Modified FGF-21 polypeptide with non-naturally encoded amino acid substitution

A modified FGF-21 polypeptide comprising a non-naturally encoded amino acid, wherein the modified FGF-21 polypeptide maintains the biological activity of human FGF-21 and comprises a sequence at least 95% identical to SEQ ID NO: 1 through SEQ ID NO: 7.

Restricted non-naturally encoded amino acid structure

The non-naturally encoded amino acid has a restricted R group, excluding the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, pyrrolysine, or selenocysteine.

Substitution at specified FGF-21 residues

The modified FGF-21 polypeptide contains a substitution of an amino acid with the non-naturally encoded amino acid at a position corresponding to residue 72, 77, 86, 108, 110, 131, or 146 of SEQ ID NO: 1.

Non-naturally encoded amino acid linked to a linker or polymer

The non-naturally encoded amino acid is linked to a linker or a polymer.

Poly(ethylene glycol) polymer embodiment

The polymer includes a poly(ethylene glycol) moiety, including a PEG moiety having a molecular weight between about 0.1 kDa and about 100 kDa.

Improved in vivo half-life

The FGF-21 polypeptide has an in vivo half-life at least two-fold greater than the human FGF-21 polypeptide in SEQ ID NO: 1.

Pharmaceutical composition with pharmaceutically acceptable carrier

A composition includes a modified FGF-21 polypeptide together with a pharmaceutically acceptable carrier.

Overall, the claim coverage is directed to biologically active modified FGF-21 polypeptides that incorporate a restricted non-naturally encoded amino acid at specified residue positions, link that amino acid to a linker or polymer including PEG, and achieve an in vivo half-life at least two-fold greater than human FGF-21. The dependent claims further specify PEG features and a pharmaceutical composition.

Stated Advantages

Maintains the biological activity of human FGF-21.

In vivo half-life at least two-fold greater than the human FGF-21 polypeptide in SEQ ID NO: 1.

Substantially homogeneous polymer:protein conjugates and altered conjugate properties are described in the patent text.

Documented Applications

Therapeutic use in Type 1 diabetes.

Therapeutic use in Type 2 diabetes (NIDDM).

Therapeutic use in obesity/insulin resistance.

Therapeutic use in critically ill patients with SIRS/respiratory distress such as ARDS.

Human Phase 1 study outline reporting safety/tolerability and comparative pharmacokinetics/half-life expectations.

Preclinical pharmacokinetic studies in rats.

Activity/affinity assessment contexts for FGF-21 preparations, including glucose uptake in 3T3-L1 adipocytes and receptor affinity by BIAcore™.

In vivo half-life and pharmacokinetics evaluation for modified FGF-21 polypeptide preparations.

Therapeutic use and administration/formulation concepts are broadly outlined.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.